The effect of transurethral resection of the prostate on lymphocyte response in patients with prostatic cancer.

The following study indicates that transurethral resection may affect the in vivo cellular aspects of the immune response in patients with prostatic cancer. This in vivo result seems to be supported by the fact that patients dying of carcinoma of the prostate at our institution usually had had an antecedent transurethral resection. Therefore, we emphasize that transurethral resection in patients with prostate cancer should be undertaken with clear-cut indications and with the knowledge that it may be an insult to the patient's immune system.

Impotence therapy and cancer of the prostate.

Prostate cancer developed in two male patients being treated with fluoxymesterone for erectile impotence. It is suggested that the current increased interest in and therapy for sexual dysfunction be accompanied by an awareness of a possible causal relationship between exogenous androgens and prostrate cancer.

The CEA test in urologic cancer: an evaluation and a review.

The diagnostic value of the carcinoembryonic antigen test was evaluated in 2,029 blood and urine samples from 308 urologic cancer patients, 13 patients with nonurologic cancer, 20 urologic patients with nonmalignant disease, and in 30 controls. The blood CEA test was positive in 50% of patients with active urologic malignancy and in 35% of patients with inactive malignancy. The urine CEA test was elevated only in patients with active bladder cancer but most of these patients had concurrently infected urines.